Childhood retinol-binding protein 4 (RBP4) levels predicting the 10-year risk of insulin resistance and metabolic syndrome: the BCAMS study

Ge Li1, Issy C. Esangbedo2, Lu Xu1, Junling Fu1, Lujiao Li1, Dan Feng3, Lanwen Han3, Xinhua Xiao1, Mingyao Li4, Jie Mi5, Ming Li1*†, Shan Gao3*† and Steven M. Willi6

Abstract

Background: Elevated retinol-binding protein 4 (RBP4) levels may contribute to the development of metabolic abnormalities, but prospective studies evaluating the association between childhood RBP4 levels and metabolic syndrome (MS) in adulthood are lacking. We investigated whether RBP4 levels during childhood predict cardiometabolic risk at 10-year follow-up.

Methods: The relationships between RBP4 levels, the established adipokines (leptin and adiponectin) and the components of MS were examined in 3445 school-aged children recruited in 2004 for the Beijing Child and Adolescent Metabolic Syndrome study. In 2015, 352 of these individuals completed an in-depth follow-up examination.

Results: Participants with higher childhood RBP4 levels had adverse cardiometabolic profiles at follow-up. Those with incident or persistent MS had higher baseline RBP4 levels than those who never exhibited the elements of MS. Moreover, baseline RBP4 predicted hyperglycemia (OR per SD increase = 1.48, \( P = 0.009 \)), elevated triglyceride (OR = 1.54, \( P < 0.001 \)), elevated blood pressures (OR = 1.46, \( P = 0.015 \)), MS (OR = 1.68, \( P = 0.002 \)) and insulin resistance (OR = 1.44, \( P = 0.015 \)) in the 10-year follow-up phase, independent of baseline BMI. Significant improvements were seen for the net reclassification improvement and integrated discrimination index after adding childhood RBP4 levels into the risk models using conventional cardiometabolic risk factors in predicting MS at follow-up (\( P < 0.05 \)). Leptin and adiponectin demonstrated the expected associations with metabolic disorders.

Conclusions: Childhood RBP4 serves as a risk factor for subsequent development of MS and its components, independent of pediatric obesity. Incorporating childhood RBP4 into conventional cardiometabolic risk assessment models significantly improves the prediction of MS.

Keywords: Retinol-binding protein 4, Insulin resistance, Metabolic syndrome, Children, Youth
Background

Childhood obesity frequently tracks into adulthood and is a vital contributor to the development of insulin resistance (IR) later in life [1]. Numerous biologically active adipokines, produced by an expanded adipose tissue mass, constitute a pathogenic link between obesity, IR and the metabolic syndrome (MS) [2, 3]. In addition to leptin and adiponectin, which are well-established biomarkers for metabolic dysfunction [2, 4], retinol-binding protein 4 (RBP4), a transport protein for retinols, has been shown to play a role in establishing the link between obesity and IR, and thereby contributes to the pathogenesis of MS and type 2 diabetes (T2D) [5–9].

While liver is the primary source of circulating RBP4, adipocytes become an important secondary source in insulin resistant states [6]. Elevations in RBP4 will induce adipose tissue inflammation and promote systemic IR [10]. Furthermore, RBP4 may play a role in the pathogenesis of T2D by upregulating hepatic expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK) and inhibiting insulin signaling in muscle [6]. Conversely, genetic deletion of RBP4 enhances insulin sensitivity [6]. Clinical studies in adults have demonstrated associations between RBP4 levels and obesity, IR, MS and T2D [5, 8, 9, 11], although not all studies agree [12–14]. A limited quantity of cross-sectional pediatric data exhibit an inconsistent relationship between RBP4 levels and childhood metabolic disorders [15–17], while prospective studies in youth remain scarce. In two longitudinal studies of overweight or obese youth, reductions in RBP4 were reported to accompany weight loss, improvement of triglyceride (TG) levels and IR [18, 19], while a small study of Korean boys reported that baseline RBP4 levels did not predict the development of MS over a 3-year follow-up [20]. These existing pediatric studies are significantly limited by their small sample sizes and relatively short follow-up periods.

Leveraging the large cohort within the Beijing Child and Adolescent Metabolic Syndrome (BCAMS) study, we aimed to examine the role of circulating RBP4 in the development of IR, MS and its components from cross-sectional data collected in childhood and longitudinal analysis into young adulthood. In addition, we investigated the incremental value of RBP4 when added to conventional cardiometabolic risk factors in predicting the 10-year risk of cardiometabolic disorders.

Methods

Subjects

The BCAMS study is an ongoing cohort study of obesity and related metabolic abnormalities (IR, hypertension, hyperglycemia, and dyslipidemia) as they track from childhood into adulthood in Beijing, China [21]. A representative sample of 19,593 school children, aged 6-18 years, were chosen from four of the eight urban districts and three of seven rural districts in the Beijing area between April and October, 2004. Among these children and adolescents, 4500 were recognized as having risk factors defined by the presence of any one of the following: overweight, total cholesterol (TC) ≥5.2 mmol/L, TG ≥1.7 mmol/L or fasting glucose (FG) ≥5.6 mmol/L based on initial finger capillary blood tests. Moreover, all subjects at increased risk for MS, together with a parallel reference population of 1095 children, were invited to undergo medical examinations for verification based on venipuncture blood samples and clinical examination. Amongst this cohort, 3445 children (50.9% boys, n = 1754) provided blood samples for RBP4 measurement and were thus included in the cross-sectional analysis at baseline. Follow-up studies of this cohort were carried out in 2014. Among the 4500 subjects who were recognized as having risk factors and 1095 normal controls (n = 5595) at baseline, 560 subjects agreed to return to complete the in-depth follow-up examination during the 2 year follow-up period [22]. Among these 560, 352 participants had baseline blood samples available to measure RBP4 levels, and thus were included in the longitudinal analysis. A consort diagram is illustrated in (Additional file 1: Figure S1). The BCAMS study has been registered at http://www.clinicaltrials.gov (NCT03421444).

Normal weight, overweight and obesity were defined by the sex- and age-specific 85th and 95th percentile of BMI, separately, as recommended by the Working Group on Obesity in China Normal weight [23]. The presence of pediatric MS at baseline was defined by the modified criteria of Adult Treatment Panel III (ATP III), which is described in detail elsewhere [24]. MS in adolescents and adults after follow-up was defined by the presence of three or more of the following five components according to the harmonized definition [22, 25]: (1) central obesity: Waist circumference (WC) ≥90th percentile for age and gender less than 18 years or WC ≥90 cm for adult males and WC ≥80 cm for adult females; (2) systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥90th percentile for age and gender for subjects less than 18 years or SBP ≥130 mmHg or DBP ≥85 mmHg for adults; (3) high-density lipoprotein cholesterol (HDL-C) ≤1.03 mmol/L in males, ≤1.29 mmol/L in females; (4) TG ≥1.70 mmol/L; (5) hyperglycemia: including impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and T2D. The IFG, IGT, and T2D definitions were based on the diagnostic criteria of the American Diabetes Association [26]. Subjects diagnosed with T2D or Type 1 diabetes (T1D) at baseline were excluded from this study. Signed informed consent was obtained from participants and/or parents/guardians. The BCAMS was
approved by the Ethics Committee at the Capital Institute of Pediatrics in Beijing. The follow-up study was approved by the Ethics Committee at Beijing Chaoyang Hospital. All the phases of the study complied with the Ethical Principles for Medical Research Involving Human Subjects expressed in the Declaration of Helsinki.

Clinical and anthropometric measurements
The participants’ height and weight were measured under standardized conditions by trained staff. BMI was calculated as weight (kg) divided by height squared (m²). WC was measured midway between the lowest rib and the top of the iliac crest at the end of a normal expiration and the mean value of 3 measurements was recorded. Percent body fat (FAT %) was assessed by bioelectrical impedance analysis (BIA, TANITA TBF-300A). SBP and DBP were measured in the right arm three times, 10 min apart, and the average of the three measurements was used in the analysis. Pubertal development was assessed by Tanner stages (T1–T5) of breast development in girls and testicular volume in boys [27]. This assessment was performed under standardized conditions by two pediatricians match in gender to the child. In addition, questionnaires were used to obtain information on physical activity and dietary intake [28].

Laboratory measurements
Venous blood samples were drawn after an overnight fast. A 2-h 75 g oral glucose tolerance test (OGTT) was performed in follow-up individuals. The concentrations of plasma glucose (glucose oxidize method), TG, TC, HDL-C and low-density lipoprotein cholesterol (LDL-C) were assayed by the Hitachi 7060 C automatic biochemistry analysis system. HbA1c was assayed using the TOSOH G7 automatic analysis system. Insulin, adiponectin and leptin were measured by monoclonal antibody based enzyme-linked immunosorbent assay (ELISA) [29], which was developed in the Key Laboratory of Endocrinology, Peking Union Medical College Hospital. Insulin assay had an inter-assay coefficient of variation (CV) of <9.0% and no cross-reactivity to proinsulin (<0.05%). The intra- and inter-assay CVs were <5.4 and <8.5% for adiponectin, and <7.4 and <9.3% for leptin, respectively [30]. RBP4 was measured by ELISA kits (Dou set, R&D Systems, Minneapolis, MN, USA) with intra- and inter-assay CVs of 6.2 and 8.5%, respectively. Insulin resistance index was calculated by homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-IR = fasting insulin (mU/L) × FG (mmol/L)/22.5 [31] or insulin sensitive index (Matsuda Index) (ISIM), ISIM = 10,000/(FG × fasting insulin) × (G × I), where G = mean serum glucose, and I = mean serum insulin concentration [32].

Statistical analysis
All values are expressed as mean±SD, if not otherwise specified. Variables with skewed distributions, including insulin, HOMA-IR, leptin and adiponectin, were transformed to natural logarithm for analyses. The Chi square test was used for categorical variables. Two-sample t test, ANOVA with LSD post hoc comparison test or general linear model with adjustment of confounders were applied to identify differences among continuous variables between two or more groups. Partial correlation analysis, controlling for confounding variables, was used to examine correlations between RBP4 and metabolic parameters. Multivariate logistic regression models were used to estimate ORs for IR, MS and its components. The area under the receiver operating characteristic (ROC) curve (AUC), i.e., c-statistic, net reclassification improvement (NRI) and integrated discrimination index (IDI) were used to evaluate the ability and improvement of models to predict MS. The AUCs of various models predicting follow-up MS were compared using Medcalc statistical software version 16.2.0, while NRI and IDI were calculated using R version 3.4.1 (http://cran.r-project.org/). All statistical analyses except NRI, IDI and AUCs comparison were performed using SPSS version 19.0 software for windows (SPSS Inc., Chicago, IL, USA). A P value of <0.05 was considered statistically significant.

Results
Findings in the cross-sectional study
A total of 3445 children were included in the cross-sectional analysis at baseline. Among them, 1285 (37.3%) had no MS components, 1737 (50.4%) had 1–2 MS components, and 423 (12.3%) were identified as having MS. Sex- and puberty-related differences of baseline RBP4 levels were evaluated. Subjects were stratified as normal weight (46.4%), overweight (18.6%) or obese (35.0%) based on the age- and gender-specific BMI percentiles. As shown in (Additional file 1: Figure S2), serum RBP4 levels in boys increased steadily with pubertal development in all three weight categories. In normal weight girls, RPB4 increased with pubertal development in parallel with the boys, but exhibited almost no change with pubertal progression in overweight and obese girls. RBP4 levels in boys were higher than in girls at T4 (P=0.045) in the normal weight group, at T4-5 (P<0.001) in the overweight group, and at T3–5 (all P<0.01) in the obese group.

The subjects were then divided into non-MS or MS group, and their baseline characteristics were listed in Table 1. As expected, participants with MS showed an adverse cardio-metabolic profile, including higher BMI, WC, FAT%, SBP, DBP, TG, TC, LDL-C, insulin, HOMA-IR and leptin levels, and lower HDL-C and adiponectin
levels. RBP4 levels at baseline were significantly higher in subjects who had MS compared with those who did not (RBP4, 38.54 ± 12.43 vs. 33.47 ± 11.19 μg/ml, P < 0.001).

**Relationship of RBP4 with IR, MS and its components in the prospective study**

To assess the effect of circulating RBP4 on long-term cardiometabolic risk at follow-up, 352 subjects who underwent an in-depth examination after 10 years were included. Among them, 110 (31.3%) had no MS components, 189 (53.7%) had 1–2 MS components, and 53 (15.1%) were identified as having MS. The characteristics of 352 subjects at baseline and follow-up are listed in (Additional file 1: Table S1). In the partial association analyses (Table 2), baseline RBP4 levels were positively correlated with the follow-up BMI, WC, SBP, DBP, TG, TC, LDL-C, ln-insulin, ln-HOMA-IR and ln-leptin levels, and negatively associated with HDL-C and ln-ISI_m (all P < 0.05) after adjustment for gender, age, puberty and time of follow-up. Additionally, leptin and adiponectin levels showed similar associations with metabolic profiles after adjusted for the above factors (data not shown).

Among the 299 participants who did not have pediatric MS at baseline, 39 subjects (13.0%) had developed MS at the 10 year follow-up visit, whereas, amongst the 53 subjects with MS at baseline, only 19 subjects (35.8%) were found to still have MS at follow-up. Subjects with incident MS had higher RBP4 levels at baseline than those without MS evident at baseline or follow-up (RBP4, 42.07 ± 14.37 μg/ml vs. 32.73 ± 9.65 μg/ml, P < 0.001 after adjustment for gender, age, puberty, physical activity and dietary intake; Fig. 1). Subjects with persistent MS had higher RBP4 levels at baseline than those with baseline MS only (RBP4, 33.47 ± 11.19 μg/ml vs. 38.54 ± 12.43 μg/ml, P = 0.010 after adjustment for the same confounding variables).

We further used multivariable logistic regression to relate baseline RBP4 levels to the risk of having MS at follow-up (Table 3; Fig. 2). To separately explore the potential roles of RBP4 in the development of MS or the
tracking of MS from childhood to adulthood, subjects were divided into two groups: non-MS and MS at baseline. In the subjects without MS at baseline, we found that an elevated RBP4 level at baseline was an independent predictor for incident MS upon follow-up (OR per 10 μg/ml (approximately 1 SD) increase 1.68, [95% CI 1.22–2.34], \( P = 0.002 \) after adjustment for age, gender, puberty, BMI, physical activity and dietary intake at baseline; Model 2; Table 3; Fig. 2). In addition, adjustment for MS component levels at baseline didn’t change the association between childhood RBP4 levels and incident MS. Moreover, although increased leptin levels and reduced adiponectin levels also predicted follow-up MS (all \( P < 0.05 \)), further adjustment for baseline leptin and adiponectin levels at baseline didn’t change the association between childhood RBP4 levels and incident MS.

### Table 2 Partial correlation coefficients between baseline RBP4 levels and metabolic parameters at the 10-year follow-up

| Parameter                  | Coefficients | \( P^a \) |
|----------------------------|--------------|-----------|
| BMI (kg/m)                 | 0.125        | 0.027     |
| WC (cm)                    | 0.132        | 0.020     |
| Fat-mass percentage (%)    | 0.065        | 0.248     |
| SBP (mmHg)                 | 0.267        | < 0.001   |
| DBP (mmHg)                 | 0.197        | < 0.001   |
| TG (mmol/L)                | 0.231        | < 0.001   |
| TC (mmol/L)                | 0.121        | 0.033     |
| HDL-C (mmol/L)             | −0.114       | 0.044     |
| LDL-C (mmol/L)             | 0.156        | 0.006     |
| Fasting glucose (mmol/L)   | 0.082        | 0.150     |
| OGTT 2 h glucose (mmol/L)  | 0.085        | 0.143     |
| HbA1c (%)                  | 0.071        | 0.200     |
| Insulin (mU/L)\( ^b \)    | 0.119        | 0.036     |
| HOMA-IR\( ^b \)           | 0.124        | 0.028     |
| ISIM\( ^b \)              | −0.137       | 0.019     |
| Adiponectin (μg/L)\( ^b \) | −0.060       | 0.296     |
| Leptin (ng/mL)\( ^b \)    | 0.121        | 0.032     |
| RBP4 (μg/mL)               | 0.152        | 0.007     |

\( BMI \): body mass index, WC: waist circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, TG: triglycerides, TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, HOMA-IR: homeostatic model assessment of insulin resistance

\( ^a \): \( P \) values were calculated from partial correlation analysis adjusted for baseline age, gender, puberty, physical activity and dietary intake.

\( ^b \): Variables were ln-transformed before analysis.

### Table 3 Baseline RBP4 levels predicts the incidence and persistence of MS in the 10-year prospective study

|          | The incidence of MS\( ^a \) | The persistence of MS\( ^b \) |
|----------|-----------------------------|------------------------------|
|          | OR/unit (95% CI)            | \( P \) | OR/unit (95% CI) | \( P \) |
| Model 1  | 1.77 (1.29–2.43)            | < 0.001 | 2.19 (1.14–4.20) | 0.018 |
| Model 2  | 1.68 (1.22–2.34)            | 0.002  | 2.32 (1.18–4.53) | 0.015 |
| Model 3  | 1.43 (1.01–2.04)            | 0.049  | 3.85 (1.51–9.84) | 0.005 |
| Model 4  | 1.66 (1.19–2.30)            | 0.003  | 2.28 (1.06–4.93) | 0.036 |

\( OR \): odds ratio for per 10 μg/ml (approximately 1 SD) increase in baseline RBP4 levels.

\( ^a \): Excludes subjects with MS at baseline.

\( ^b \): Excludes subjects without MS at baseline.

Model 1: adjusted for age, gender, and pubertal stage at baseline.

Model 2: Model 1 + additionally adjusted with physical activity, dietary score, and BMI at baseline.

Model 3: Model 1 + additionally adjusted with waist circumference, systolic blood pressure, HDL-C, fasting blood glucose and TG levels at baseline.

Model 4: Model 1 + additionally adjusted with adiponectin, leptin levels and BMI at baseline.

### Figures

**Fig. 1** The mean and standard error of serum RBP4 levels at baseline according to metabolic syndrome (MS) status at baseline and follow-up. \( P \) values were calculated from the general linear model adjusting for age, gender and puberty, physical activity and dietary intake.

**Fig. 2** OR (95% CI) for each 10 μg/ml (approximately 1 SD) increase in baseline RBP4 levels for the novel development of metabolic syndrome (MS) in subjects not affected at baseline or the persistence of MS among subjects with MS at baseline and at 10-year follow-up. ORs were adjusted for age, gender, pubertal stage, waist circumference, systolic blood pressure, HDL-C, fasting blood glucose, and TG levels at baseline.
adiponectin didn’t modify the associations between baseline RBP4 and follow-up MS ($P = 0.003$; Model 4).

In the group having MS at baseline, we found that an elevated RBP4 level at baseline was also associated with an increased risk of persistent MS at follow-up (OR 3.85, [95% CI 1.51–9.84], $P = 0.005$; Model 3; Table 3) independent of conventional metabolic risk factors at baseline. Additionally, adjustment for baseline leptin and adiponectin didn’t modify the associations between baseline RBP4 and persistent MS ($P = 0.036$; Model 4).

With respect to the key elements of MS, after adjusting for age, gender and puberty (Model 1, Table 4), RBP4 levels at baseline predicted IR (OR per 10 μg/ml (approximately 1 SD) increase in baseline RBP4 levels was $0.785$ (95% CI 0.716–0.853). Adding RBP4 levels to the models including MS components increased the AUC (0.813, 95% CI 0.747–0.880) with marginal significance ($P = 0.062$). However, using the more sensitive statistical measures of NRI and IDI, significant improvement was seen between models with and without RBP4 levels. The continuous NRI for adding RBP4 levels was 0.376 (95% CI 0.083–0.669, $P = 0.012$), suggesting that the percentage of individuals with MS correctly classified upward and those without MS correctly classified downward was 37.6% using a model adding RBP4 compared with the initial model including only MS components. The IDI was 0.046 (95% CI 0.011–0.082, $P = 0.011$), indicating that the difference in average predicted risks between individuals with and without the outcome increased significantly when RBP4 was included in the prediction model.

**Discussion**

In this cohort study of Chinese youth, high levels of childhood RBP4 at baseline were associated with an adverse cardiovascular risk profile at baseline and upon 10-year follow-up. The most striking, novel finding of the present study is that RBP4 levels measured in childhood were strong predictors of the subsequent development of MS and each of its components (including IR, hyperglycemia, hypertension and hyperlipidemia) 10 years later, independent of obesity. In addition, our data are among the first to confirm the tracking of MS in Chinese children, as has been demonstrated in a number of other cohort studies [33]. Finally, the prognostic value of baseline RBP4

### Table 4 Baseline RBP4 levels predicts IR and MS components after 10-year follow-up

| Number of cases/total number of subjects | Model 1 | Model 2 | Model 3 | Model 4 |
|-----------------------------------------|---------|---------|---------|---------|
| IR (HOMA-IR ≥ 3.0)                      | 73/352  | 1.42 (1.08–1.86) | 0.011 | 1.44 (1.07–1.92) | 0.015 | 1.36 (1.02–1.81) | 0.039 | 1.35 (1.01–1.81) | 0.049 |
| Central obesity                         | 152/352 | 1.20 (0.95–1.50) | 0.125 | 1.25 (0.99–1.57) | 0.065 | 1.00 (0.74–1.35) | 0.979 | 1.00 (0.74–1.34) | 0.974 |
| Elevated blood pressure                 | 75/352  | 1.38 (1.07–1.76) | 0.012 | 1.46 (1.08–1.99) | 0.015 | 1.38 (1.01–1.91) | 0.049 | 1.33 (1.01–1.76) | 0.046 |
| Reduced HDL-C                           | 58/352  | 1.08 (0.80–1.47) | 0.612 | 1.05 (0.77–1.45) | 0.756 | 1.09 (0.78–1.52) | 0.609 | 1.04 (0.75–1.43) | 0.830 |
| Elevated TG                             | 61/352  | 1.83 (1.40–2.41) | <0.001 | 1.76 (1.33–2.33) | <0.001 | 1.54 (1.14–2.07) | 0.004 | 1.70 (1.28–2.26) | <0.001 |
| Hyperglycemia                           | 44/352  | 1.49 (1.11–1.99) | 0.008 | 1.48 (1.10–1.98) | 0.009 | 1.55 (1.14–2.09) | 0.005 | 1.51 (1.12–2.03) | 0.007 |

OR indicates odds ratio for per 10 μg/ml (approximately 1 SD) increase in baseline RBP4 levels

BMI body mass index, HOMA-IR homeostatic model assessment of insulin resistance, IR insulin resistance, TG triglycerides, HDL-C high-density lipoprotein cholesterol, MS metabolic syndrome.

Model 1: adjusted for age, gender and pubertal stage at baseline

Model 2: Model 1 + additionally adjusted with physical activity, dietary score, and baseline BMI (except central obesity model)

Model 3: Model 2 + additionally adjusted with levels of the individual components at baseline

Model 4: Model 1 + additionally adjusted with adiponectin, leptin levels and BMI at baseline.
levels led us to uncover the first epidemiological evidence that incorporating childhood RBP4 levels into a risk assessment model using MS components significantly enhances the prediction of subsequent development of MS. Our study also replicated well-known associations between leptin, adiponectin and metabolic disorders.

**Sex-, puberty- and weight status-related differences in RBP4 levels at baseline**

As a result of the wide range of ages found in our relatively large sample of Chinese children, we were able to assess pubertal influences on RBP4 and found that this effect was modified by adiposity and differed by gender. We noted that RBP4 levels in boys increased consistently across puberty regardless of their weight status; whereas in girls, this increase in RBP4 across puberty was only evident in the absence of obesity, suggesting a sexual dimorphism in RBP4 levels with regard to obesity. Although the effect of puberty on RBP4 has previously been examined in three small, cross-sectional studies of European and Korean children, those findings were inconsistent; likely due to the small sample size (n < 130) in each [34–36]. Our findings contribute significantly to the limited data available on RBP4 levels in puberty, and thereby allow us to identify which age stage and degree of adiposity might determine RBP4-associated pathologic events and expand our understanding of the pubertal influences on metabolic disorders. Although the precise mechanism is unclear, this finding suggests that any evaluation of the importance of RBP4 in metabolic disorders of children should take gender and puberty into account.

**Relationship of RBP4 with IR and hyperglycemia at follow-up**

Our data identify a longitudinal association between circulating RBP4 levels and IR, as well as hyperglycemia. Animal studies have demonstrated RBP4’s pivotal role in IR [10]. Consistent with these experimental observations, childhood RBP4 levels exhibited a reverse association with insulin sensitivity at baseline and were predictive of IR at 10-year follow-up in our study. As IR predisposes one to develop T2D, we found that subjects with the highest levels of RBP4 in childhood had the greatest risks of developing hyperglycemia during the 10-years follow-up phase, although there was a very low incidence of T2D after just 10 years of follow-up (at a mean age of 20.2). Further adjustment for baseline BMI did not change the longitudinal association between RBP4 and dysglycemia, suggesting that this association is not merely a reflection of childhood obesity. Consistent with our results, several adult studies have found strong associations between IR, T2D and elevated RBP4 levels [5, 8, 11], while others fail to endorse these relationships [12–14]. However, the current study presents some of the only prospective pediatric data on RBP4 levels and their association with IR aside from a few cross-section studies with relatively small sample size [15, 16, 34, 37]. The other existing longitudinal data are from rather small studies, but were nonetheless, consistent with our findings [18, 20]. Therefore, our long-term prospective study provides substantial evidence supporting the vital role of RBP4 during childhood in the determination of dysglycemia early in life.

**Relationship of RBP4 with MS at follow-up**

The most significant finding of this study is the identification of RBP4’s potential role in the tracking of childhood MS. Nearly 36% of children with MS showed persistence of this condition at 10 year follow-up. Although this is lower than what is found in previous studies [34, 38, 39], it is difficult to compare results across studies due to the inconsistent definition of MS applied. Nonetheless, we believe this is the first study to examine the tracking of MS from childhood to adulthood in a Chinese population [40]. The significance of RBP4 is highlighted by the observations that RBP4 elevations in childhood were present in both those with incident MS at follow-up, as well as those with MS which persisted over 10 years. Of the many possible pathophysiological mechanisms involved in the development and maintenance of MS, we believe that RBP4 is a reliable indicator of innate IR [10], and plays an important role, given its longitudinal association with IR and its ability to predict the onset and persistence of MS after 10-year follow-up. In contrast to a study in seventy overweight/obese adolescent girls from Eastern Europe [41], it is worthy to note that even after adjusting for obesity and the components of MS at baseline, childhood RBP4 levels still predicted MS and its components in our study, suggesting an independent role for RBP4 in the development of MS. Moreover, although the value of other adipokines (e.g., leptin and adiponectin) has been previously established [2], after adjusting for the contribution of adiponectin and leptin, childhood RBP4 levels still predicted MS and its components. Taken together, these are the first prospective data providing evidence that increased RBP4 levels in early childhood confers a risk for not only the development but also the persistence of MS into adulthood.

**Improvement of risk model combining RBP4 levels and metabolic risk factors in predicting MS**

Despite strong evidence of the association between RBP4 and metabolic abnormalities, there are limited data on the predictive value of circulating RBP4 for the
development of MS. Moreover, previous studies did not evaluate the additional predictive ability of RBP4 beyond the information based on MS components at baseline. In our study, we performed three measures (AUC, NRI, and IDI) to estimate the practical value of RBP4 in addition to components of the MS. While the traditional MS components at baseline strongly informed the prediction of MS at 10 years follow-up in our study, adding childhood RBP4 levels to these risk factors still significantly improves the ability to predict MS at follow-up, as indicated by the continuous NRI and the IDI. It should be noted, that NRI and IDI appear to be more sensitive than the AUC, particularly when risk factors with strong associations to the outcome have already been included in the initial model [42]. As a result, the improvement of AUCs showed a marginal significance in this study. However, there are still limitations and controversies surrounding these two measures, including the possibility of miscalibration of prediction models [43]. Nonetheless, to our knowledge this is the first prospective cohort study to indicate that circulating RBP4 may have intrinsic value in screening for cardiometabolic risk during childhood. Future studies are needed to further delineate specific risk scoring tools and clinical thresholds for predicting MS using serum RBP4.

**Strength and limitation**

The major strength of our study is the assembly of a large, well-characterized cohort of subjects with a range of metabolic traits and covariates. The wide array of phenotyping information allows us to adjust for many potential confounders known to correlate with both cardiometabolic risk and RBP4 levels, ensuring a robust analysis. Nevertheless, our study has several potential limitations. Firstly, we could not avoid the possibility of introducing selection bias, as the number of subjects returning for follow-up evaluation after 10 years was relatively small compared to the original cohort, mainly due to enhanced migration patterns among school-aged children in Beijing, and the inherent difficulties of tracking subjects from childhood into adulthood. Nonetheless, the salient characteristics of subjects available for follow-up was similar to the overall cohort at baseline, although BMI, WC, TG, HOMA-IR and leptin were slightly higher than in those lost to follow-up (Additional file 1: Table S2). As these are among the only longitudinal data on RBP4 across childhood, further prospective studies with larger sample size from diverse pediatric populations are warranted to validate our findings. Secondly, although we have taken into account numerous confounding factors in a variety of statistical models compared to previous studies, we could not adjust for all potential confounders, such as kidney function. An adult study (n = 230) and a small pediatric study (n = 85) was reported that kidney function was associated with circulating RBP4 levels [44, 45], but we didn’t measure kidney function of children at baseline. This may be a possible limitation, although no significant association between serum creatinine and RBP4 levels was observed at follow-up after adjustment for age and gender (P > 0.05, data not shown). Thirdly, due to the relatively small number of subjects with MS in the follow-up phase, we chose to adjust our logistic regression models for a limited number of important covariates in a single model, in order to avoid introducing artifact by “over adjusting” the model.

In conclusion, in this young Chinese population, circulating RBP4 levels predict the development of MS and its components, independent of pediatric obesity. Adding RBP4 levels to MS components improves the ability to assess the risk of incident and persistent MS over a 10-year period. Thus, our prospective cohort study provides new insight into the potential role of RBP4 as an early biomarker of MS, and may constitute a future target for interventions.

**Additional file**

**Additional file 1: Figure S1.** Flow chart. Figure S2. Gender- and puberty- differences in serum RBP4 levels. Table S1. Baseline and follow-up characteristics of subjects in the prospective study. Table S2. Baseline characteristics of subjects with or without loss to follow-up.

**Abbreviations**

BMI: body mass index; DBP: diastolic blood pressure; FBG: fasting blood glucose; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: the index of homeostasis model assessment of insulin resistance; IDI: integrated discrimination index; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; ISIM: insulin sensitive index (Matsuda Index); LDL-C: low-density lipoprotein cholesterol; MS: metabolic syndrome; NRI: net reclassification improvement; OGTT: oral glucose tolerance test; ROC: receiver operating characteristic; SBP: systolic blood pressure; T2D: type 2 diabetes; TC: total cholesterol; TG: triglycerides; WC: waist circumference.

**Authors’ contributions**

GL analyzed data and wrote the manuscript. LX, JLF, LYL, DF, LWH and HXX contributed to data collection in the BCAMS; ICE, and MYL contributed to the data analysis, and reviewed the manuscript; JM directed the implementation of BCAMS; SG was responsible for the follow-up study; SMW contributed to the design, data interpretation, and edited the manuscript. ML was responsible for the concept, design of the work, and contributed to interpretation of the data, and revised the manuscript. All authors read and approved the final manuscript.

**Author details**

1 Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, 1 Shuishuyuan, Wangfujing, Dongcheng District, Beijing 100730, China. 2 Health Weight Program, The Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA 19104, USA. 3 Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China. 4 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA. 5 Department of Epidemiology, Capital Institute of Paediatrics, Beijing 100020, China.
Department of Endocrinology/Diabetes, The Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA 19104, USA.

Acknowledgements

The authors thank the BCMAS participants for their continuing participation in this research effort.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All datasets used in the current investigation are available from the corresponding author upon reasonable request.

Consent for publication

All authors have read and approved the final version of the manuscript before submission. If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.

Disclosure statement

The author reports no conflicts of interest in this work.

Ethics approval and consent to participate

The study was approved by the local ethics committee and is in accordance with the declaration of Helsinki on ethical principles for medical research involving human subjects. Written informed consent was obtained from all patients before participation in this study.

Funding

This work was supported by grants from key program of Beijing Municipal Science &Technology Commission (#D11110000611001, #D11110000611002) and partly by grants from National Key Research program of China (2016YFC1304801), Beijing Natural Science Foundation (#7172169), Development Program of Beijing Chaoyang Hospital (JYXJP201606), Beijing Science & Technology Star Program (#2004A027), Novo Nordisk Union Diabetes Research and partly by grants from National Key Program of Clinical Science (#WBYZ 2011-873).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 January 2018 Accepted: 21 April 2018
Published online: 14 May 2018

References

1. Tailor AM, Peeters PH, Norat T, Vineis P, Romaguera D. An update on the prevalence of the metabolic syndrome in children and adolescents. Int J Pediatr Obes. 2010;5:202–13.
2. Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36:461–70.
3. Chung HS, Lee MJ, Hwang SY, Lee HJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, et al. Circulating angiopoietin-like protein 8 (ANGPTL8) and ANGPTL3 concentrations in relation to anthropometric and metabolic profiles in Korean children: a prospective cohort study. Cardiovasc Diabetol. 2016;15:1.
4. Jornayvaz FR, Vollenweider P, Bochud M, Mosser V, Vaeger G, Marques-Vidal P. Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study. Cardiovasc Diabetol. 2016;15:73.
5. Graham TE, Yang Q, Bluher M, Hammerstedt RA, Caraldi TP, Henry RR, Wason CJ, Obertach A, Jansson PA, Smith U, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New Engl J Med. 2006;354:2522–63.
6. Yang Q, Graham TE, Mody N, Prentner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–62.
7. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007;92:1971–4.
8. Qi Y, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007;92:4827–34.
9. Lim S, Yoon JW, Choi SH, Park YJ, Lee JJ, Park JH, Lee SB, Kim KW, Lim JY, Kim YB, et al. Combined impact of adiponectin and retinol-binding protein 4 on metabolic syndrome in elderly people: the Korean Longitudinal Study on Health and Aging. Obesity. 2010;18:826–32.
10. Moraes-Vieira PM, Yore MM, Dwyer PM, Syed I, Aryal P, Kahn BB. RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab. 2014;19:512–6.
11. Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, Xiang K. Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab. 2007;92:5224–9.
12. Prommert Z, Krebs M, Todoric J, Luger A, Bischof MG, Nowotny P, Wagner O, Esterbauer H, Anderwald C. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007;92:4306–12.
13. Broch M, Vendrell J, Ricart W, Richard C, Fernandez-Realt JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care. 2007;30:1802–6.
14. Ulgen F, Herder C, Kuhn MC, Willenberg HS, Schott M, Scherbaum WA, Schinner S. Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients. Arch Physiol Biochem. 2010;116:57–62.
15. Kanaka-Gantenbein C, Margelis A, Pervanidou P, Sakka S, Mastorakos G, Chrousos GP, Papassotiriou I. Retinol-binding protein 4 and lipocortin-2 in childhood and adolescent obesity: when children are not just “small adults”? Clin Pharmacol Ther. 2008;84:1176–82.
16. Aeberli I, Biebinger R, Lehmann R, Ullemann D, Spinas GA, Zimmermann MB. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab. 2007;92:4359–65.
17. Kim IK, Lee HJ, Kang JH, Song J. Relationship of serum retinol-binding protein 4 with weight status and lipid profile among Korean children and adults. Eur J Clin Nutr. 2011;65:226–33.
18. Reinehr T, Stoffel-Wagner B, Roth CL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93:2877–93.
19. Goodman E, Graham TE, Dolan LM, Daniels SR, Goodman ER, Kahn BB. The relationship of retinol binding protein 4 to changes in insulin resistance and cardiometabolic risk in overweight adolescents. J Pediatr. 2009;154(67–73):e61.
20. Choi KY, Yannakoulia M, Park MS, Cho GJ, Kim JH, Lee SH, Hwang TG, Yang SJ, Kim TN, Yoo HJ, et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr. 2011;93:19–26.
21. Li M, Fisette A, Zhao XY, Deng JY, Mi J, Cianflone K. Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes. 2009;33:424–39.
22. Fu J, Hou C, Li L, Feng D, Li G, Li M, Li C, Gao S, Li M. Vitamin D modifies circulating retinol binding protein and protein C inhibitor. J Intern Med. 2015;277:305–11.
23. Group of China Obesity Task Force. Body mass index reference norm for Chinese children and adolescents. Int J Obes. 2009;33:424–39.
24. Fu J, Hou C, Li L, Feng D, Li G, Li M, Li C, Gao S, Li M. Vitamin D modifies the associations between circulating betatrophin and cardiometabolic risk factors among youths at risk for metabolic syndrome. Cardiovasc Diabetol. 2016;15:142.
25. Group of China Obesity Task Force. Body mass index reference norm for screening overweight and obesity in Chinese children and adolescents. Chin J Epidemiol. 2004;25:97–102.
26. Wang Q, Yin J, Xu L, Cheng H, Zhao X, Xiang H, Lam HS, Mi J, Li M. Prevalence of metabolic syndrome in a cohort of Chinese schoolchildren: comparison of two definitions and assessment of adipokines as components by factor analysis. BMC Public Health. 2013;13:249.
37. Saki F, Ashkani-Esfahani S, Karamizadeh Z. Investigation of the relation between insulin sensitivity and obesity: data from the BCAMS study. J Clin Endocrinol Metab. 2016;101:1816–25.

28. Li L, Yin J, Cheng H, Wang Y, Gao S, Li M, Grant SF, Li C, Mi J, Li M. Identification of genetic and environmental factors predicting metabolically healthy obesity in children. J Diabetes Mellit. 2019;13:214–7.

27. Marshall WA, Tanner JM. Puberty. In: Falkner F, Tanner JM, editors. Human Growth. New York: Plenum Press; 1986. p. 171–210.

26. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–66.

25. Santoro N, Perrone L, Cirillo G, Brienza C, Grandone A, Cresta N, del Giudice EM. Variations of retinol binding protein 4 levels are not associated with fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

24. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.

23. Juonala M, Magnusson CG, Venn A, Dwyer T, Burns TL, Davis PH, Chen W, Srinivasan SR, Daniels SR, Kahonen M, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122:2514–20.

22. Friebe D, Neef M, Erbs S, Dittrich K, Kratzsch J, Kovacs P, Bluher M, Kiess W, Korner A. Retinol binding protein 4 (RBP4) is primarily associated with adipose tissue mass in children. Int J Pediatr Obes. 2011;6:e345–52.

21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

20. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

19. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

18. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

17. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

16. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–66.

15. Santoro N, Perrone L, Cirillo G, Brienza C, Grandone A, Cresta N, del Giudice EM. Variations of retinol binding protein 4 levels are not associated with fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

14. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.

13. Juonala M, Magnusson CG, Venn A, Dwyer T, Burns TL, Davis PH, Chen W, Srinivasan SR, Daniels SR, Kahonen M, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122:2514–20.

12. Friebe D, Neef M, Erbs S, Dittrich K, Kratzsch J, Kovacs P, Bluher M, Kiess W, Korner A. Retinol binding protein 4 (RBP4) is primarily associated with adipose tissue mass in children. Int J Pediatr Obes. 2011;6:e345–52.

11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

10. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

9. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

8. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

7. Li M, Wu C, Song A. Development and preliminary application of enzyme-linked immunosorbent assay for human net insulin in serum. Chin J Diabetes Mellit. 1997;13:214–7.

6. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–66.

5. Santoro N, Perrone L, Cirillo G, Brienza C, Grandone A, Cresta N, del Giudice EM. Variations of retinol binding protein 4 levels are not associated with fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.